News | September 03, 2025
Novartis Leqvio demonstrates strong LDL-C goal achievement with reduced muscle pain
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction1
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Transformation to pure-play Innovative Medicines company nears completion
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
Subscribe To Our Newsletter & Stay Updated
